Unlocking the Potential

Matt Kaeberlein discusses the challenges of conducting clinical trials for aging-related diseases and the potential of interventions like Rapamycin. He emphasizes the need for identifying the right endpoints and highlights the Tame trial as one strategy. Matt also shares his thoughts on the current drug regulation system and the misplaced concerns about side effects.